Literature DB >> 35848761

PEComa-like Neoplasms Characterized by ASPSCR1-TFE3 Fusion: Another Face of TFE3-related Mesenchymal Neoplasia.

Pedram Argani1,2, Sara E Wobker3,4, John M Gross1,2, Andres Matoso1,2,5, Christopher D M Fletcher6, Cristina R Antonescu7.   

Abstract

Identical TFE3-related gene fusions may be found in renal cell carcinoma and mesenchymal neoplasms such as alveolar soft part sarcoma and TFE3-rearranged perivascular epithelioid cell tumor (PEComa). Among mesenchymal neoplasms, the ASPSCR1-TFE3 gene fusion has previously been described only in alveolar soft part sarcoma. We report 3 unusual mesenchymal neoplasms harboring the ASPSCR1-TFE3 gene fusion, the morphologic phenotype of which more closely matches PEComa rather than alveolar soft part sarcoma. All 3 neoplasms occurred in females ranging in age from 18 to 34 years and were located in the viscera (kidney, bladder, and uterus). All 3 contained nests of epithelioid cells bounded by fibrovascular septa. However, all were associated with hyalinized stroma, tight nested architecture, mixed spindle cell and epithelioid pattern, clear cytoplasm, and lacked significant discohesion. Overall, morphologic features closely resembled PEComa, being distinct from the typical alveolar soft part sarcoma phenotype. While none of the neoplasms labeled for HMB45, cytokeratin, or PAX8 all showed positivity for TFE3 and cathepsin K, and all except 1 were positive for smooth muscle actin. One patient developed a liver metastasis 7 years after nephrectomy. These cases bridge the gap between 2 TFE3-rearranged neoplasms, specifically alveolar soft part sarcoma and Xp11 translocation PEComa, highlighting the relatedness and overlap among Xp11 translocation neoplasms. While most TFE3-rearranged neoplasms can be confidently placed into a specific diagnostic category such as alveolar soft part sarcoma, PEComa, or Xp11 translocation renal cell carcinoma, occasional cases have overlapping features, highlighting the potential role that the cell of origin and the specific gene fusion play in the phenotype of these neoplasms.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35848761      PMCID: PMC9298479          DOI: 10.1097/PAS.0000000000001894

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.298


  25 in total

1.  PSF/SFPQ is a very common gene fusion partner in TFE3 rearrangement-associated perivascular epithelioid cell tumors (PEComas) and melanotic Xp11 translocation renal cancers: clinicopathologic, immunohistochemical, and molecular characteristics suggesting classification as a distinct entity.

Authors:  Qiu Rao; Qin Shen; Qiu-yuan Xia; Zi-yu Wang; Biao Liu; Shan-shan Shi; Qun-li Shi; Hong-lin Yin; Bo Wu; Sheng-bing Ye; Li Li; Jie-Yu Chen; Min-hong Pan; Qing Li; Rui Li; Xuan Wang; Ru-song Zhang; Bo Yu; Heng-hui Ma; Zhen-feng Lu; Xiao-jun Zhou
Journal:  Am J Surg Pathol       Date:  2015-09       Impact factor: 6.394

2.  Identification of a novel PARP14-TFE3 gene fusion from 10-year-old FFPE tissue by RNA-seq.

Authors:  Weihua Huang; Michael Goldfischer; Sabina Babayeva; Yong Mao; Konstantin Volyanskyy; Nevenka Dimitrova; John T Fallon; Minghao Zhong
Journal:  Genes Chromosomes Cancer       Date:  2015-05-29       Impact factor: 5.006

3.  A novel partner of TFE3 in the Xp11 translocation renal cell carcinoma: clinicopathological analyses and detection of EWSR1-TFE3 fusion.

Authors:  Hironori Fukuda; Ikuma Kato; Mitsuko Furuya; Reiko Tanaka; Toshio Takagi; Tsunenori Kondo; Yoji Nagashima
Journal:  Virchows Arch       Date:  2018-12-14       Impact factor: 4.064

4.  Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas.

Authors:  Marion Classe; Gabriel G Malouf; Xiaoping Su; Hui Yao; Erika J Thompson; Denaha J Doss; Valérie Grégoire; Julien Lenobin; Jean-Christophe Fantoni; Hélène Sudour-Bonnange; David Khayat; Sébastien Aubert; Nizar M Tannir; Xavier Leroy
Journal:  Histopathology       Date:  2017-03-21       Impact factor: 5.087

5.  PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21).

Authors:  Pedram Argani; Cristina R Antonescu; Jérôme Couturier; Jean-Christophe Fournet; Raf Sciot; Maria Debiec-Rychter; Brian Hutchinson; Victor E Reuter; Lilliane Boccon-Gibod; Charles Timmons; Naiel Hafez; Marc Ladanyi
Journal:  Am J Surg Pathol       Date:  2002-12       Impact factor: 6.394

6.  Dichotomy of Genetic Abnormalities in PEComas With Therapeutic Implications.

Authors:  Narasimhan P Agaram; Yun-Shao Sung; Lei Zhang; Chun-Liang Chen; Hsiao-Wei Chen; Samuel Singer; Mark A Dickson; Michael F Berger; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2015-06       Impact factor: 6.394

7.  TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.

Authors:  Pedram Argani; Minghao Zhong; Victor E Reuter; John T Fallon; Jonathan I Epstein; George J Netto; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2016-06       Impact factor: 6.394

8.  Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay.

Authors:  Pedram Argani; Priti Lal; Brian Hutchinson; Man Yee Lui; Victor E Reuter; Marc Ladanyi
Journal:  Am J Surg Pathol       Date:  2003-06       Impact factor: 6.394

9.  Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma.

Authors:  Cristina R Antonescu; Francois Le Loarer; Juan-Miguel Mosquera; Andrea Sboner; Lei Zhang; Chun-Liang Chen; Hsiao-Wei Chen; Nursat Pathan; Thomas Krausz; Brendan C Dickson; Ilan Weinreb; Mark A Rubin; Meera Hameed; Christopher D M Fletcher
Journal:  Genes Chromosomes Cancer       Date:  2013-06-05       Impact factor: 5.006

10.  RNA sequencing of Xp11 translocation-associated cancers reveals novel gene fusions and distinctive clinicopathologic correlations.

Authors:  Xiao-Tong Wang; Qiu-Yuan Xia; Sheng-Bing Ye; Xuan Wang; Rui Li; Ru Fang; Shan-Shan Shi; Ru-Song Zhang; Xiao Tan; Jie-Yu Chen; Ke Sun; Xiao-Dong Teng; Heng-Hui Ma; Zhen-Feng Lu; Xiao-Jun Zhou; Qiu Rao
Journal:  Mod Pathol       Date:  2018-04-30       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.